CDXS News and Press, Codexis Inc. From 02/27/20

Codexis, Inc. (CDXS) Q4 2019 Earnings Conference Call February 27, 2020 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations John Nicols - President and Chief Executive Officer Ross Taylor - Chief Financial Officer Conference Call Participants Matt Hewitt - Cr...

The following slide deck was published by Codexis, Inc. in conjunction with their 2019 Q4 earnings Read more ...

Codexis (NASDAQ: CDXS ): Q4 Non-GAAP EPS of $0.02 misses by $0.03 ; GAAP EPS of -$0.01 misses by $0.01 . More news on: Codexis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

2019 total revenues increased 13% to $68.5 million with product revenue up 15% and R&D revenue up 11%  Ten customers contributed more than $1 million each to 2019 revenues Introduces 2020 financial guidance Conference call with slides begins at 4:30 pm Eastern time to...

Long-term shareholders who believed in the technology platform of  Codexis (NASDAQ: CDXS) have largely been rewarded for their patience. The stock rose from obscurity to deliver a 360% gain from the beginning of 2017 to late 2018. The company's market cap soared from less than $250 milli...

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences: Cowen and Company 40 th Annual Health Care Conference on Tuesday, March 3 at 1...

REDWOOD CITY, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2019 fourth quarter and full year financial results after market close on Thursday, February 27, 2020. Codexis management will hold an i...

Dosing is underway in a Phase 1 clinical trial evaluating Rubius Therapeutics' ( RUBY -4.5% ) lead candidate RTX-134, an allogeneic off-the-shelf cell therapy, for the potential treatment of phenylketonuria (PKU), a rare inborn error of metabolism characterized by the buildup of the am...

Genetic medicines and cellular therapies have an enormous potential to treat, and possibly cure, currently untreatable diseases. Nonetheless, it's important for investors to remember that "simpler" treatment options won't become obsolete just because gene therapy, gene editing, and immunotherapy...

CHONGQING, China, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) today announced that it has attended the official opening of Porton Pharma Solutions Ltd.’s (SZSE: 300363) fermentation pilot laboratory located in Porton’s Changshou site, achieving another impor...